710121Sentinel Oncology – Optimisation of Chk1 inhibitors for treatment of GlioblastomaClosedGRD Proof of ConceptInnovate UKGlioblastoma is a cancer of the brain which, although relatively rare, has a very poor survival rate. It is particularly deadly in young patients and overall survival for all patient groups over 5 years is less than 3%. One reason for the poor prognosis and survival rate is that the available treatments have progressed very little over the past 30 years, with surgery followed by radiotherapy being the only real option. Glioblastoma tumours rapidly develop resistance to treatment and the aim of this project will be to develop a drug with the ability to reverse that resistance and make the existing therapies effective once more.